Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 748 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... June 30, 2022 Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... February 1, 2023 Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... April 6, 2021 Cómo solicitar Medicare cuando tiene cáncer December 12, 2023 Load more HOT NEWS Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung... Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... Improving research with registered reports
